REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 7th, 2023 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 7th, 2023 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of August 4, 2023, by and between Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business at 9390 Towne Center Drive, Suite 200, San Diego, California, 92121 and Astellas US, LLC, a Delaware limited liability company (the “Purchaser”), with its principal place of business at 2375 Waterview Drive, Northbrook, IL 60062 and shall become effective as of the Closing.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 7th, 2023 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 7th, 2023 Company Industry JurisdictionTHIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), is being entered into as of August 4, 2023, by and between Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business at 9390 Towne Centre Drive, Suite 200, San Diego, California 92121 and Astellas US, LLC, a Delaware limited liability company (the “Purchaser”) with its principal place of business at 2375 Waterview Drive, Northbrook, IL 60062. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Letter Agreement • August 7th, 2023 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 7th, 2023 Company Industry JurisdictionThis strategic rights letter agreement (this “Letter Agreement”) will confirm our agreement that as partial inducement for Astellas US LLC (“Astellas”) to enter into that certain Securities Purchase Agreement, dated as of the date hereof, by and between Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), and Astellas (the “Purchase Agreement”), the Company shall grant Astellas certain rights pursuant to the terms and conditions set forth in this Letter Agreement. Each of Astellas and the Company are also referred to herein individually as a “Party” and together as the “Parties.”